AI-Powered Precision Medicine in the Future of Healthcare

Tempus AI (NASDAQ: TEM) is leading a transformation in healthcare by using artificial intelligence to deliver personalized medical solutions. 

With an $11 billion market cap and partnerships with industry leaders like AstraZeneca, Tempus leverages 300 petabytes of genomic data and tools like the Olivia AI assistant to dominate the $50 billion AI healthcare market. 

Its work in accelerating oncology research and matching patients to clinical trials positions it as a top pick for tech investors looking to capitalize on precision medicine’s growth.

Next AI Boom (Sponsored)

These 9 AI Stocks Could Be the Biggest Stories of the Year

Tensions between the U.S. and China are rewriting the rules of the AI economy — and Wall Street is already adjusting.

Nvidia is taking a hit from new export restrictions, but several smaller, U.S.-based players are quietly stepping into the spotlight.

A newly released report highlights 9 under-the-radar AI stocks that are already aligned with Washington’s new direction — and may see outsized upside as a result.

These names offer deep AI exposure, domestic infrastructure, and momentum most investors haven’t noticed yet.

Access our FREE report, "Top 9 AI Stocks for This Month" to discover these opportunities before the broader market catches on.

Operational Overview and Recent Earnings

Tempus delivers three main services: genomic testing for oncology and hereditary conditions, data licensing for pharma and biotech, and AI applications to optimize patient care and research. 

Its Genomics segment, which generates 76% of revenue, focuses on cancer and hereditary testing, while Data Services (24%) licenses insights from 40 million patient records. AI tools like Olivia and Tempus One enhance trial matching and patient engagement.

In Q1 2025, Tempus reported $256 million in revenue, up 75% year-over-year. The Ambry Genetics acquisition drove Genomics revenue to $194 million, an 89% increase, with oncology tests rising 31% to 75,000 and hereditary tests up 23% to 78,000. 

Data Services grew 43% to $62 million, boasting 74% gross margins. The adjusted EBITDA loss shrank to $16 million from $44 million, beating estimates by $7 million, though cash burn rose to $108 million due to growth investments.

In 2024, revenue grew 30% to $1 billion, but 2025’s surge reflects Tempus’s ability to scale. Its network reaches 65% of U.S. academic medical centers and 50% of oncologists, providing unmatched access. 

Gross profit jumped 99.8% in Q1, and improving margins show operational discipline, even as the company invests heavily in expansion.

Sector Incentive Stocks (Sponsored)

7 Hidden Stocks Set to Lead This Quarter

The second quarter has brought a wave of volatility, but also rare opportunity.

A just-released investor guide reveals seven stocks positioned to lead Q2, based on deep research and market momentum.

These companies have one thing in common: big upside with limited crowd exposure.

From energy to biotech, this report uncovers where the smart money is flowing.

Claim the full list now before institutional buyers drive up prices.

[Get Your Free Guide Now]

Competitive Edge in Precision Medicine

Tempus stands out by combining scale, technology, and partnerships. Its 40 million patient records and 300 petabytes of data surpass competitors like Guardant Health, enabling AI tools that match patients to clinical trials 30% faster than traditional methods. 

A $150 million R&D budget, 12% of revenue, supports innovations like the xT CDx test, priced at $4,500, which has raised average selling prices to $1,590.

Acquisitions are strengthening its position. The $600 million Ambry deal, closed in February 2025, expands hereditary and cardiovascular testing, while the March 2025 acquisition of Deep6 AI improves trial recruitment across 750 provider sites. 

These moves have boosted data licensing retention to 140%. Partnerships with AstraZeneca, Pfizer, and GSK, including a $200 million oncology deal, solidify Tempus’s role as a trusted pharma partner. 

Unlike Flatiron Health, which focuses solely on data analytics, Tempus offers a comprehensive platform covering testing, AI, and trial matching.

With 4,000 institutional ties and scalable AI, Tempus leads in oncology, where speed and accuracy are critical. Its Olivia app, which helps patients navigate health data, is gaining traction, strengthening ties with providers and boosting engagement.

Hidden Crypto Gems (Sponsored)

The Next Big Crypto Play Isn’t Bitcoin and It May Be Closer Than You Think

Bitcoin is breaking records. But behind the scenes, a different story is unfolding — one that could catch many investors off guard.

Altcoins are quietly staging their own rally:

→ 100%, 300%, even 1,000%+ moves in some cases
→ Inflow records from major institutions
→ Policy changes accelerating mainstream crypto adoption

A new report reveals how to navigate the current setup — and how to potentially position ahead of what could be a massive rotation into select altcoins.

This updated crypto guide includes:

✔ The signals behind explosive altcoin moves
✔ A simple approach to identifying pre-run momentum
✔ The #1 altcoin setup right now — revealed as a free bonus

Access to this complete research package is just $5.60, but only for the next 48 hours.

[Get instant access here]

Bear Case

Investing in Tempus comes with hurdles:

• Guardant Health’s liquid biopsy tests, such as Guardant360, are competitive and could erode Tempus’s market share. 

• Regulatory delays, like MolDx’s pending approval for minimal residual disease (MRD) tests, may hinder new launches. 

• Quarterly cash burn of $108 million, with $219 million in cash reserves, raises dilution risks if growth slows. 

• Economic slowdowns could tighten hospital budgets.

• Integration challenges from Ambry and Deep6 could disrupt operations. 

• Data privacy concerns also pose a litigation risk, which could shake investor confidence.

Tempus AI’s Precision Play Heals Tech Portfolios

Tempus is poised for a breakout year. Management projects $1.25 billion in 2025 revenue, an 80% increase from 2024’s 30% growth, per Q1 filings. Genomics will account for 60% of this growth, with hereditary testing expanding post-Ambry. 

Data Services, with $940 million in remaining contract value, is expected to grow 40% annually, driven by pharma deals. Adjusted EBITDA is forecast to turn positive at $5 million in 2025, a $110 million improvement, signaling a path to profitability.

A 25% organic growth rate, combined with plans for xH whole-genome sequencing by 2026, keeps Tempus ahead of competitors. 

Regulatory risks, such as MolDx delays, could create short-term challenges, but its data scale and institutional reach provide stability. 

New initiatives, like 1,000 AI agents integrated into hospital EHR systems and a Q2 2025 immunotherapy assay, position Tempus to capture more of the oncology market and ultimately combine to make this a standout MedTech stock for the long run.